These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38310626)

  • 21. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
    Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
    J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of combined parenteral and oral steroid therapy in Graves' orbitopathy.
    Nedeljkovic Beleslin B; Ciric J; Zarkovic M; Stojkovic M; Savic S; Knezevic M; Stankovic B; Trbojevic B
    Hormones (Athens); 2014; 13(2):222-8. PubMed ID: 24776622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
    Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
    Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
    Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
    Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.
    Riedl M; Kolbe E; Kampmann E; Krämer I; Kahaly GJ
    J Endocrinol Invest; 2015 Feb; 38(2):177-82. PubMed ID: 25576458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.
    Bartalena L; Krassas GE; Wiersinga W; Marcocci C; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Veronesi G; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G;
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4454-63. PubMed ID: 23038682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves' Orbitopathy.
    Stoynova MA; Shinkov AD; Georgiev GK; Kovatcheva RD
    Curr Eye Res; 2021 Oct; 46(10):1503-1508. PubMed ID: 33849364
    [No Abstract]   [Full Text] [Related]  

  • 28. DIAGNOSTIC ACCURACY OF BASAL CORTISOL LEVEL TO PREDICT ADRENAL INSUFFICIENCY IN COSYNTROPIN TESTING: RESULTS FROM AN OBSERVATIONAL COHORT STUDY WITH 804 PATIENTS.
    Struja T; Briner L; Meier A; Kutz A; Mundwiler E; Huber A; Mueller B; Bernasconi L; Schuetz P
    Endocr Pract; 2017 Aug; 23(8):949-961. PubMed ID: 28614010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy.
    Kemchoknatee P; Tangon D; Srisombut T
    BMC Ophthalmol; 2023 Jan; 23(1):32. PubMed ID: 36690985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new less-invasive and more informative low-dose ACTH test: salivary steroids in response to intramuscular corticotrophin.
    Contreras LN; Arregger AL; Persi GG; Gonzalez NS; Cardoso EM
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):675-82. PubMed ID: 15579180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
    Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
    Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
    Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy.
    Ueda-Sakane Y; Kanamoto N; Fushimi Y; Tanaka-Mizuno S; Yasuno S; Miura M; Sone M; Yasoda A; Okada T; Togashi K; Nakao K; Inagaki N
    Endocr J; 2016 Aug; 63(8):703-14. PubMed ID: 27263854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of clinical outcome in patients with moderate/severe Graves' orbitopathy undergoing treatment with parenteral glucocorticoids: a retrospective study.
    Le Moli R; Naselli A; Costanzo G; Piticchio T; Tumino D; Pellegriti G; Frasca F; Belfiore A
    Front Endocrinol (Lausanne); 2024; 15():1401155. PubMed ID: 39027472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy.
    Miśkiewicz P; Jankowska A; Brodzińska K; Milczarek-Banach J; Ambroziak U
    Int J Endocrinol; 2018; 2018():1978590. PubMed ID: 30420883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism.
    Le Moli R; Malandrino P; Russo M; Lo Giudice F; Frasca F; Belfiore A; Vigneri R
    Front Endocrinol (Lausanne); 2020; 11():367. PubMed ID: 32595602
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of epidural methylprednisolone acetate injection on the hypothalamic-pituitary-adrenal axis.
    Habib G; Jabbour A; Salman J; Hakim G; Haddad H
    J Clin Anesth; 2013 Dec; 25(8):629-33. PubMed ID: 23988802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in ocular biomechanics after treatment for active Graves' orbitopathy.
    Li HX; Zhao XH; Song Y; Mu BK; Pan Y; Zhao H; Wang Y
    J Endocrinol Invest; 2021 Mar; 44(3):453-458. PubMed ID: 32507991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?
    Bartalena L; Veronesi G; Krassas GE; Wiersinga WM; Marcocci C; Marinò M; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G; Perros P; Kahaly GJ;
    J Endocrinol Invest; 2017 May; 40(5):547-553. PubMed ID: 28176220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucocorticoid induced adrenal insufficiency is common in steroid treated glomerular diseases - proposed strategy for screening and management.
    Karangizi AHK; Al-Shaghana M; Logan S; Criseno S; Webster R; Boelaert K; Hewins P; Harper L
    BMC Nephrol; 2019 May; 20(1):154. PubMed ID: 31060510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.